



UNITED STATES PATENT AND TRADEMARK OFFICE

16 OCT 2006

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER NJ 07936-1080

In re Application of	:	
BETZ, Michael et al.	:	
Application No.: 10/520,570	:	
PCT No.: PCT/EP03/07346	:	DECISION ON
Int. Filing Date: 08 July 2003	:	
Priority Date: 09 July 2002	:	PETITION
Attorney Docket No.: BP/G-32576A/BCK	:	
For: LIQUID FORMULATIONS WITH A	:	UNDER 37 CFR 1.47(a)
HIGH CONCENTRATION OF HUMAN	:	
GROWTH HORMONE (HGH)	:	
COMPRISING GLYCINE	:	

This is a decision on applicants' submission of an executed declaration, filed in the United States Patent and Trademark Office (USPTO) on 16 August 2006.

BACKGROUND

On 30 June 2006, the Office mailed Decision On Petition Under 37 CFR 1.47(a), dismissing applicants' petition without prejudice.

On 16 August 2006, applicants submitted an executed declaration of the previously non-signing inventor.

DISCUSSION

The 16 August 2006 declaration satisfies 37 CFR 1.497(a)-(b).

CONCLUSION

For the above reasons, applicants' petition under 37 CFR 1.47(a) is **DISMISSED AS MOOT**.

This application is being forwarded to the National Stage Processing Branch of the Office of PCT Operations to continue national stage processing of the application. The application has a 35 U.S.C. §371(c)(1), (c)(2) and (c)(4) date of **16 August 2006**.

Erin P. Thomson

Erin P. Thomson
Attorney Advisor
PCT Legal Administration

Telephone: 571-272-3292
Facsimile: 571-273-0459